dia76ca, very good post.
1) Historically we hardly could gather sufficient cash to look more then 6 months ahead.
2) We then came into the 25isch Milj$ cash range good for about a year.
3) We now are at 41.6Milj$ Cash, good to close fiscal year 2014 (Q1/2015 in our fiscal calendar), including all possible PIII plans/cost till then.
4) As of the Annual Meeting our going concern will be officially gone (history after all these years).
From now (actually JUL 2013) till and included Q1/2015 ALL Avid profits (19 months of Production) may be added to that because as PL stated the current cash on itself would bring us already to Q1/2015.
CSM settlement is a bonus to that, EVEN if it is just payback of the cost for salvaging our NSCLC clinical trial and if NO damages AT ALL would be granted, because it would in all cases add to our cash position.
So actually we are much longer good then Q1/2015. It gives us the additional flexibility, as mentioned by PL, in partner talks. This as well for Cotara in Japan as for Bavi partnering or Bavi oncology buy-out. I can see a partnership specific for Imaging too and I would not be surprised that we get some extra 3rd part orders, including some gov/BARDA related. We seem to have the attention for those gov production orders as sub-contractor and as posted by someone, some of Avid's customers are doing very good themselves and their success and related production drug needs will reflect on Avid's production as well! In this area I wouldn't be surprised if the forecasts for Avid will be set higher again in the Annual.
News 
Market Data 
Discover 
AI
